User:Gabaidoro/sandbox

Michel Goldman (born 1 January 1955) is a Belgian medical doctor who specialized in immunology.

Biography
He graduated as a Medical Doctor (1978) at the Université Libre de Bruxelles (ULB), Belgium, received his PhD in medical sciences (1981) at the Université de Genève and was board certified in internal medicine (1984) and clinical biology (1993).

From 1990 to 2008, he was the Head of the Department of Immunology-Hematology-Transfusion at the Erasme Hospital of the Université Libre de Bruxelles (ULB) and from 2004 to 2009 he serves as the first Director of the Institute for Medical Immunology at ULB.

From 2009 to 2014, Michel Goldman, MD, PhD, was the first Executive Director of the Innovative Medicines Initiative Joint Undertaking (IMI). With a budget of 2 billions € provided jointly by the European Federation of Pharmaceutical Industries and Associations and the European Commission, he was responsible for 59 public-private consortia in areas of major importance, including antimicrobial resistance, Alzheimer's dementia, autism, diabetes, immuno-inflammatory disorders, chronic pulmonary diseases and drug safety.

Currently, Michel Goldman is Professor of Immunology and Pharmacotherapy at ULB. Furthermore, he is a member of the Board of Directors of CQDM (Canadian consortium for precompetitive research), of the Board of the Tuberculosis Vaccine Initiative and of the Strategic and Scientific Advisory Board of GenomeQuebec. He is also the Chairman of the Scientific Committee of Effimune S.A., a French biotechnology company.

As of September 2015, Michel Goldman will serve as the first Director of the Institute for Interdisciplinary Innovation in Healthcare (I3h) newly created by ULB to foster research, education and outreach networks for the benefit of patients and other stakeholders.

Michel Goldman’s scientific achievements resulted in more than 400 articles in peer-reviewed journals and he was recognized as ISI Highly Cited Scientist in 2006 by the Thomson Institute for Scientific Information. In 2000 he received the Joseph Maisin Prize, a major award for clinical sciences delivered by the Fonds National de la Recherche Scientifique (Belgium) and he held in 2001 the Spinoza chair at the University of Amsterdam, the Netherlands. In 2007, Michel Goldman was awarded the degree of Doctor Honoris Causa of the Université Lille II, France.

Awards and recognition

 * 1992: Medical Prize Lucien Steinberg (shared with Pr. Peter Piot)


 * 1999: Francqui Chair at the University of Namur


 * 2000: Quinquiennal Prize of the Belgian National Fund for Scientific Research for Clinical Sciences


 * 2001: Spinoza Chair at the University of Amsterdam


 * 2003: Francqui Chair at the University of Liège


 * 2006: Highly Cited Scientist recognition by the Thomson Institute for Scientific Information


 * 2007: Doctor Honoris Causa degree of the University of Lille 2

Biomedical Research

 * Goldman M, Rose LM, Hochmann A, Lambert PH. (1982). Deposition of idiotype-anti-idiotype immune complexes in renal glomeruli after polyclonal B cell activation. | Journal of Experimental Medicine 155 : 1385-1399.


 * Cogan E, Schandené L, Crusiaux A, Cochaux P, Velu T, Goldman M. (1994). Clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. | New England Journal of Medicine 330 : 535-538.


 * Marchant A., Devière J, Byl B, De Groot D, Vincent JL, Goldman M. (1994). Interleukin-10 production during septicaemia. | Lancet 343 : 707-708.


 * Tassignon J, Ismaili J, Le Moine A, Van Laethem F, Leo O, Vandevelde M, Goldman M. (1999). Azodicarbonamide inhibits T cell responses in vitro and in vivo. | Nature Medicine 5 : 947-950.


 * Goldman M, Le Moine A, Braun M, Flamand V, Abramowicz D. (2001) A role for eosinophils in transplant rejection | Trends in Immunology 22 : 247-251.


 * Le Moine A, Goldman M. (2003) Non-classical pathways of cell-mediated allograft rejection: new challenges for tolerance induction ? | American Journal of Transplantation 3 : 101-106.


 * Wraith D, Goldman M, Lambert PH. (2003) Vaccines and autoimmunity: what is the evidence ? | Lancet 362 : 1659.


 * Goriely S, Van Lint C, Dadkah R, Libin M, De Wit D, Demonte D, Willems F, Goldman M. (2004). A defect in nucleosome remodeling prevents IL-12(p35) gene transcription in neonatal dendritic cells. | Journal of Experimental Medicine 199 : 1011-1016.


 * Goriely S, Neurath MF, Goldman M. (2008) How microorganisms tip the balance between interleukin-12 family members. | Nature Reviews Immunology 8 : 82-86.


 * Garçon N, Goldman M. (2009) Boosting vaccine power. | Scientific American 301: 72-79.

Research and innovation policy

 * Goldman M. (2012) Public-private partnerships need honest brokering. | Nature Medicine, 18: 341.


 * Goldman M. (2013) New frontiers for collaborative research. | Science Translational Medicine 5, 216ed22.


 * Goldman M, Seigneuret N, Eichler H.-G. (2014) The Innovative Medicines Initiative: An engine for regulatory science. | Nature Reviews Drug Discovery, doi:10.1038/nrd4520.


 * Murphy D, Goldman M, Loth E, Spooren W. (2014) Public-private partnership: a new engine for translational research in neurosciences. | Neuron, 84:533-536.


 * Gunn M, Lim M, Cross D, Goldman M. (2015) Public-private partnership for health innovation: time to assess research performance. Nature Biotechnology, in press.